Capstone Investment Advisors, LLC Cardiff Oncology, Inc. Transaction History
Capstone Investment Advisors, LLC
- $38 Billion
- Q2 2025
A detailed history of Capstone Investment Advisors, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Capstone Investment Advisors, LLC holds 51,190 shares of CRDF stock, worth $117,225. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,190
Previous 51,190
-0.0%
Holding current value
$117,225
Previous $160,000
0.63%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CRDF
# of Institutions
127Shares Held
24.2MCall Options Held
1.01MPut Options Held
293K-
Vanguard Group Inc Valley Forge, PA3.59MShares$8.22 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$6.02 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.21MShares$5.07 Million0.01% of portfolio
-
Laurion Capital Management LP New York, NY1.8MShares$4.12 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA1.54MShares$3.53 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $99.2M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...